Ketoconazole with Sirolimus Interaction Details
Brand Names Associated with Ketoconazole
- Ketoconazole
- Nizoral®
Brand Names Associated with Sirolimus
- Rapamune®
- Rapamycin
- Sirolimus

Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Dec 02, 2023
Interaction Effect
An increased risk of sirolimus toxicity (anemia, leukopenia, thrombocytopenia, hypokalemia, diarrhea)
Interaction Summary
Sirolimus is extensively metabolized by CYP3A4 and is a substrate of the p-glycoprotein transporter system. Ketoconazole is a potent CYP3A4 and p-glycoprotein inhibitor. Coadministration of sirolimus and ketoconazole is not recommended due to the potential for significantly increased plasma concentrations of sirolimus and may lead to sirolimus toxicity.
Severity
Major
Onset
Delayed
Evidence
Established
How To Manage Interaction
Coadministration of sirolimus and ketoconazole, a potent CYP3A4/p-glycoprotein inhibitor, is not recommended. Consider alternative antifungal therapy. If it is necessary to prescribe sirolimus together with ketoconazole, monitor whole blood trough concentrations of sirolimus during concurrent therapy as well as monitor for sirolimus toxicity.
Mechanism Of Interaction
Inhibition of cytochrome P450 3A4 and p-glycoprotein-mediated sirolimus metabolism
Literature Reports
A) A study of the administration of two 5 mg doses of sirolimus, the first alone, the second with concomitant oral ketoconazole 200 mg daily for 10 days at steady-state, resulted in a significant increase sirolimus whole blood concentrations. The study included 23 healthy volunteers, 8 women and 15 men. The sirolimus maximum concentration (Cmax), time to Cmax (tmax) increased 4.3-fold and1.4-fold, respectively. Area under the concentration-time curve (AUC (0-144 h)) increased 11-fold (297 +/- 93 vs. 3319 +/- 1048 ng/h/mL). The terminal half-life of sirolimus was not changed. Single doses of sirolimus had no effect on the steady-state 12-hour plasma concentrations of ketoconazole .
Ketoconazole Overview
-
Ketoconazole is used to treat fungal infections when other medications are not available or cannot be tolerated. Ketoconazole should not be used to treat fungal meningitis (infection of the membranes surrounding the brain and spinal cord caused by a fungus) or fungal nail infections. Ketoconazole is in a class of antifungals called imidazoles. It works by slowing the growth of fungi that cause infection.
Sirolimus Overview
-
Sirolimus is used in combination with other medications to prevent rejection of kidney transplants. Sirolimus is in a class of medications called immunosuppressants. It works by suppressing the body's immune system.
Return To Our Drug Interaction Homepage
Feedback, Question Or Comment About This Information?
Ask Dr. Brian Staiger, PharmD, our medical editor, directly! He's always more than happy to assist.
Definitions
Severity Categories
Contraindicated
These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.
Major
This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.
Moderate
This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.
Minor
While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.
Onset
Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.
Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.
Evidence
Level of documentation of the interaction.
Established: The interaction is documented and substantiated in peer-reviewed medical literature.
Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.
How To Manage The Interaction
Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.
It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.
Mechanism Of Interaction
The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.
Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.
Where Does Our Information Come From?
Information for our drug interactions is compiled from several drug compendia, including:
The prescribing information for each drug, as published on DailyMED, is also used.
Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.
The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.